Koyfin Home > Directory > Health Care > Acorda Therapeutics > EBITDA

Acorda Therapeutics EBITDA Chart (ACOR)

Acorda Therapeutics annual/quarterly EBITDA from 2010 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Acorda Therapeutics EBITDA for the quarter ending June 06, 2020 was $-14m a -63.14% increase of 9m year over year
  • Acorda Therapeutics EBITDA for the last 12 months ending June 06, 2020 was $-62m a -50.66% increase of 31m year over year
  • Acorda Therapeutics Annual EBITDA for 2019 was $-83m a 227.75% decrease of -188m from 2018
  • Acorda Therapeutics Annual EBITDA for 2018 was $106m a -28.53% decrease of -30m from 2017
  • Acorda Therapeutics Annual EBITDA for 2017 was $136m a 91.30% increase of 124m from 2016
Other Income Statement Metrics:
  • Acorda Therapeutics Net Income for the quarter ending December 12, 2018 was $10m a 185.45% increase of 18m year over year
  • Acorda Therapeutics Total Revenue for the quarter ending December 12, 2018 was $69m a -53.52% decrease of -37m year over year
View Chart On Koyfin

Quarterly ACOR EBITDA Data

06/2020$-14m
03/2020$-22m
12/2019$-2m
09/2019$-23m
06/2019$-26m
03/2019$-31m
12/2018$-13m
09/2018$53m
06/2018$55m
03/2018$10m

Annual ACOR EBITDA Data

2019$-83m
2018$106m
2017$136m
2016$12m
2015$60m
2014$54m
2013$38m
2012$30m
2011$54m
2010$-4m